Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction
The Korean Journal of Internal Medicine
;
: 595-606, 2023.
Artículo
en Inglés
| WPRIM
| ID: wpr-1003051
ABSTRACT
With the increasing number of medications demonstrating mortality benefits in heart failure with reduced ejection fraction (HFrEF), the pharmacological treatment of HFrEF is entering a new phase. To enhance outcomes in heart failure patients through medical treatment, the choice of appropriate medications and simultaneous and rapid uptitration are critical. However, there are several challenges encountered during this medication uptitration, including issues like hypotension, fatigue, worsening renal function, and hyperkalemia. This paper addresses strategies for effectively managing these challenges to successfully reach the maximum tolerated dose in patients. Additionally, it will discuss the management of comorbidities often associated with heart failure, the importance of exercise and rehabilitation, and the significance of proper nutrition intake, in addition to guideline-directed medical therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
The Korean Journal of Internal Medicine
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS